Q-omics provides the consensus-scored MIR4514 profile across patient tissues and cancer cell-line models. MIR4514 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MIR4514 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, MIR4514 RNA expression shows 6,682 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, LUSC, and STAD as cancer lineages where MIR4514 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4514 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4514 survival associations across molecular data types. MIR4514 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4514 RNA expression–survival associations across cancer types. High MIR4514 expression shows unfavorable associations in COAD, CHOL, MESO, ACC, THCA and LGG. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for MIR4514 RNA expression.
This table summarizes MIR4514 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4514. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4514 shows lower tumor expression in LUSC, KIRP, LUAD, HNSC, THCA and KICH. The LUSC box plot shows higher MIR4514 RNA expression in normal versus tumor tissue (log2 FC = −0.425, t-test p < 0.001).
This table shows molecular features associated with MIR4514 in patient tissues and cancer cell lines. In patient samples, MIR4514 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
